Free Trial
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free BON Stock Alerts

Bon Natural Life (BON) Competitors

Bon Natural Life logo
$1.35 0.00 (0.00%)
Closing price 06/12/2026 03:49 PM Eastern
Extended Trading
$1.42 +0.08 (+5.56%)
As of 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BON vs. LTRN, TVGN, ATYR, HYPD, and ELUT

Should you buy Bon Natural Life stock or one of its competitors? MarketBeat compares Bon Natural Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bon Natural Life include Lantern Pharma (LTRN), Tevogen Bio (TVGN), aTyr Pharma (ATYR), Hyperion DeFi (HYPD), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry.

How does Bon Natural Life compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Lantern Pharma has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Lantern Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$17.12M-$1.45N/A
Bon Natural Life$18.67M0.59-$2MN/AN/A

Bon Natural Life's return on equity of 0.00% beat Lantern Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern PharmaN/A -198.34% -129.08%
Bon Natural Life N/A N/A N/A

In the previous week, Bon Natural Life had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Bon Natural Life and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat Bon Natural Life's score of 1.38 indicating that Lantern Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Lantern Pharma Very Positive
Bon Natural Life Positive

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Bon Natural Life beats Lantern Pharma on 6 of the 9 factors compared between the two stocks.

How does Bon Natural Life compare to Tevogen Bio?

Bon Natural Life (NASDAQ:BON) and Tevogen Bio (NASDAQ:TVGN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

0.6% of Bon Natural Life shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bon Natural Life has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market.

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 855.11%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
Tevogen Bio N/A N/A -472.77%

In the previous week, Tevogen Bio had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 4 mentions for Tevogen Bio and 3 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.38 beat Tevogen Bio's score of 0.97 indicating that Bon Natural Life is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bon Natural Life
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tevogen Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bon Natural Life has higher revenue and earnings than Tevogen Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.59-$2MN/AN/A
Tevogen BioN/AN/A-$26.27M-$4.61N/A

Summary

Bon Natural Life and Tevogen Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Bon Natural Life compare to aTyr Pharma?

Bon Natural Life (NASDAQ:BON) and aTyr Pharma (NASDAQ:ATYR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Bon Natural Life has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than aTyr Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.59-$2MN/AN/A
aTyr Pharma$190K227.27-$74.12M-$0.73N/A

In the previous week, Bon Natural Life had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Bon Natural Life and 2 mentions for aTyr Pharma. Bon Natural Life's average media sentiment score of 1.38 beat aTyr Pharma's score of 0.61 indicating that Bon Natural Life is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bon Natural Life
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bon Natural Life's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
aTyr Pharma N/A -100.14%-73.55%

aTyr Pharma has a consensus price target of $21.00, suggesting a potential upside of 4,668.39%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
aTyr Pharma
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Bon Natural Life and aTyr Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Hyperion DeFi presently has a consensus target price of $5.65, suggesting a potential upside of 107.72%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, research analysts clearly believe Hyperion DeFi is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperion DeFi
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 26.5% of Bon Natural Life shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hyperion DeFi has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Hyperion DeFi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperion DeFi$810K50.91-$45.31M-$9.95N/A
Bon Natural Life$18.67M0.59-$2MN/AN/A

In the previous week, Hyperion DeFi and Hyperion DeFi both had 3 articles in the media. Bon Natural Life's average media sentiment score of 1.38 beat Hyperion DeFi's score of 0.41 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperion DeFi
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bon Natural Life
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bon Natural Life's return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperion DeFiN/A -91.59% -73.08%
Bon Natural Life N/A N/A N/A

Summary

Hyperion DeFi beats Bon Natural Life on 7 of the 13 factors compared between the two stocks.

How does Bon Natural Life compare to Elutia?

Elutia (NASDAQ:ELUT) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Elutia had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.38 beat Elutia's score of 0.72 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elutia
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bon Natural Life
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Elutia has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to Bon Natural Life's net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
Elutia312.09% N/A -53.97%
Bon Natural Life N/A N/A N/A

Elutia currently has a consensus target price of $6.00, suggesting a potential upside of 525.00%. Given Elutia's stronger consensus rating and higher possible upside, analysts clearly believe Elutia is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elutia
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Elutia has higher earnings, but lower revenue than Bon Natural Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elutia$12.29M3.34$53.38M$0.861.12
Bon Natural Life$18.67M0.59-$2MN/AN/A

74.0% of Elutia shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Elutia beats Bon Natural Life on 10 of the 13 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BON vs. The Competition

Export
MetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ Exchange
Market Cap$10.98M$1.48B$7.37B$12.05B
Dividend YieldN/A4.47%2.97%5.66%
P/E RatioN/A8.7120.7824.42
Price / Sales0.592.934.25123.88
Price / CashN/A16.2613.4237.92
Price / Book0.191.433.766.82
Net Income-$2M$61.32M$246.38M$337.56M
7 Day Performance2.27%3.44%2.17%1.16%
1 Month Performance3.85%5.14%4.29%3.16%
1 Year Performance-11.76%5.91%8.21%30.60%

Bon Natural Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BON
Bon Natural Life
1.134 of 5 stars		$1.35
flat		N/A-11.8%$10.98M$18.67MN/A100
LTRN
Lantern Pharma
1.4054 of 5 stars		$3.88
flat		N/A+27.2%$43.88MN/AN/A20
TVGN
Tevogen Bio
2.2525 of 5 stars		$10.47
flat		$100.00
+855.1%		-83.1%$43.56MN/AN/A3
ATYR
aTyr Pharma
3.7333 of 5 stars		$0.44
flat		$21.00
+4,668.4%		-91.5%$43.18M$190KN/A53
HYPD
Hyperion DeFi
4.1505 of 5 stars		$2.72
flat		$5.65
+107.7%		+11.5%$41.24M$810KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BON) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel